Insulin Resistance in NAFLD: Potential Mechanisms and Therapies

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 38-54

  Samuel, Varman T ^a   Shulman, Gerald I ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Glucose; Insulin resistance; Metabolic disorders; Nonalcoholic fatty liver disease (NAFLD); Type 2 diabetes

Indexed keywords

EID: 34249745884     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch4     Document Type: Chapter

References (63)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J Am Med Assoc 2003; 289: 76-9.
2. Wolfe RR. Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. New York: Wiley-Liss, 1992.
3. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
4. Stumvoll M, et al. Renal glucose production and utilization: new aspects in humans. Diabetologia 1997; 40: 749-57.
5. Mithieux G, Bady I, Gautier A, et al. The induction of control genes in intestine gluconeogenesis is sequential during fasting and maximal in diabetes. Am J Physiol EndocrinolMetab 2004; 286: E370-5.
6. Croset M, Rajas F, Zitoun C, et al. Rat small intestine is an insulin-sensitive gluconeogenic organ. Diabetes 2001; 50: 740-6.
7. Beringer A, Thaler H. [Quantitative studies of glycogen content of the liver in normal and sick persons. II. The influence of fructose and glucose on glycogen storage.] Wien Klin Wochenschr 1964; 76: 627-30.
8. Beringer A, Thaler H. [On quantitative studies of the glycogen content of the liver in healthy and diseased subjects. III. Action mechanism of glucagon.] Wien Med Wochenschr 1965; 115: 105-7.
9. Wahren J, Felig P, Cerasi E, et al. Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus. J Clin Invest 1972; 51: 1870-8.
10. Landau BR. Limitations in the use of [U-13C6] glucose to estimate gluconeogenesis. Am J Physiol 1999; 277: E408-13.
11. Landau BR. Quantifying the contribution of gluconeo- genesis to glucose production in fasted human subjects using stable isotopes. Proc Nutr Soc 1999; 58: 963-72.
12. Landau BR, Fernandez CA, Previs SF, et al. A limitation in the use of mass isotopomer distributions to measure gluconeogenesis in fasting humans. Am J Physiol 1995; 269: E18-26.
13. Rothman DL, et al. Quantitation of hepatic glycogeno- lysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991; 254: 573-6.
14. Taylor R, et al. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996; 97: 126-32.
15. Petersen KF, et al. Contribution of net hepatic glycogen synthesis to disposal of an oral glucose load in humans. Metabolism 2001; 50: 598-601.
16. Petersen KF, et al. Contribution of net hepatic glyco- genolysis to glucose production during the early postprandial period. Am J Physiol 1996; 270: E186-91.
17. Magnusson I, et al. Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-7.
18. Landau BR, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996; 98: 378-85.
19. Chandramouli V, et al. Quantifying gluconeogenesis during fasting. Am J Physiol 1997; 273: E1209-15.
20. Jones JG, et al. An integrated 2H and 13C NMR study of gluconeogenesis and TCA cycle flux in humans. Am J Physiol EndocrinolMetab 2001; 281: E848-56.
21. Jones JG, et al. Quantitation of gluconeogenesis by 2H nuclear magnetic resonance analysis of plasma glucose following ingestion of 2^O. Anal Biochem 2000; 277: 121-6.
22. Burgess SC, et al. Analysis of gluconeogenic pathways in vivo by distribution of 2H in plasma glucose: comparison of nuclear magnetic resonance and mass spectrometry. Anal Biochem 2003; 318: 321-4.
23. Kunert O, et al. Measurement of fractional whole-body gluconeogenesis in humans from blood samples using 2H nuclear magnetic resonance spectroscopy. Diabetes 2003; 52: 2475-82.
24. Petersen K, et al. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 1998; 101: 1203-9.
25. Perseghin G, et al. Metabolic defects in lean non-diabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997; 46: 1001-9.
26. Krssak M, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999; 42: 113-6.
27. Perseghin G, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a aH-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48: 1600-6.
28. Perseghin G, et al. Increased glucose transport- phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996; 335: 1357-62.
29. Roden M, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-65.
30. Dresner A, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3- kinase activity. J Clin Invest 1999; 103: 253-9.
31. Yu C, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)- associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-6.
32. Griffin ME, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-4.
33. Lin X, et al. Protein kinase C-theta participates in NF-kB activation induced by CD3-CD28 costimulation through selective activation of IkB kinase p. Mol Cell Biol 2000; 20: 2933-40.
34. Yuan M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IkKp. Science 2001; 293: 1673-7.
35. Kim JK, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46.
36. Gao Z, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kB kinase complex. J Biol Chem 2002; 277: 48115-21.
37. Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
38. Aguirre V, et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-7.
39. Itani SI, et al. Increased protein kinase C theta in skeletal muscle of diabetic patients. Metabolism 2001; 50: 553-7.
40. Hundal RS, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6.
41. Saltiel AR Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
42. Kido Y, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105: 199-205.
43. Previs SF, et al. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 2000; 275: 38990-4.
44. Cross DA, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
45. Merkel M, et al. Lipoprotein lipase expression exclusively in liver: a mouse model for metabolism in the neonatal period and during cachexia. J Clin Invest 1998; 102: 893-901.
46. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001; 98: 7522-7.
47. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168-81.
48. Kim JK, Gavrilova O, Chen Y, et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000; 275: 8456-60.
49. Kim SP, Ellmerer M, van Citters GW, et al. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate- fat diet in the dog. Diabetes 2003; 52: 2453-60.
50. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.
51. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-8.
52. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-50.
53. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
54. Katsuki A, Sumida Y, Urakawa H, et al. Neither homeostasis model assessment nor quantitative insulin sensitivity check index can predict insulin resistance in elderly patients with poorly controlled type 2 diabetes mellitus. J Clin EndocrinolMetab 2002; 87: 5332-5.
55. Ferrara CM Goldberg AP. Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care 2001; 24: 245-9.
56. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1-7.
57. Sanyal A, Campbell-Sargent C, Clore J. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
58. Hundal R, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9.
59. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
60. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
61. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-85.
62. Mayerson AB, Hundal RS, Dufour S. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
63. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91.